Exact Sciences Corporation (Nasdaq: EXAS), a prominent healthcare company specializing in molecular diagnostics, has been maintained at a Buy rating by Citigroup, who raised the price target from $100 to $130.

Despite $EXAS closing at $95.05 on Thursday, the revised price target indicates a potential upside of $34.95 or approximately 36.75%, based on Citigroup's analysis.

Monday.com Ltd. (Nasdaq: MNDY), a leading work operating system provider, was also maintained at a Buy rating by Citigroup, with an increased price target from $167 to $224.

With Thursday's closing price at $176.76, the adjusted price target implies a potential upside of $47.24 or about 26.68% for $MNDY, as per the investment firm's view.

Workiva Inc. (NYSE: WK), a provider of cloud-based enterprise solutions for data collaboration, was maintained at a Buy rating by Citigroup, who raised the price target from $110 to $128.

Despite closing at $100.22 on Thursday, the adjusted price target reflects a potential upside of $27.78 or approximately 27.73% for $WK, based on Citigroup's assessment.

Boston Scientific Corporation (NYSE: BSX), a leading medical device company, was also maintained at a Buy rating by Citigroup, with the price target raised from $60 to $63.

Based on Thursday's closing price of $54.64, the adjusted price target suggests a potential upside of $8.36 or about 15.29% for $BSX, according to the investment firm's perspective.

These price targets and potential upsides are based on the assessments and views of Citigroup, indicating the projected appreciation in stock value according to their analysis and expectations. Investors should carefully consider these opinions while making investment decisions. 

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)